PARP inhibitors as a new therapeutic option in metastatic prostate cancer: a systematic review

2020 ◽  
Vol 23 (4) ◽  
pp. 549-560 ◽  
Author(s):  
Raffaele Ratta ◽  
Annalisa Guida ◽  
Florian Scotté ◽  
Yann Neuzillet ◽  
Asmahane Benmaziane Teillet ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Systematic Review ◽  
Metastatic Prostate Cancer ◽  
Therapeutic Option ◽  
Parp Inhibitors

Passive-specific immunotherapy with monoclonal antibodies for prostate cancer: A systematic review

2018 ◽  
Vol 25 (4) ◽  
pp. 903-917 ◽  
Author(s):  
Neda Khalili ◽  
Mahsa Keshavarz-Fathi ◽  
Sepideh Shahkarami ◽  
Armin Hirbod-Mobarakeh ◽  
Nima Rezaei
Keyword(s):  
Prostate Cancer ◽  
Systematic Review ◽  
Monoclonal Antibodies ◽  
Advanced Prostate Cancer ◽  
Search Strategy ◽  
Specific Immunotherapy ◽  
Therapeutic Option ◽  
Grey Literature ◽  
Statistical Heterogeneity ◽  
Specific Antigens

Introduction Treatment of metastatic castration-resistant prostate cancer with conventional therapies is still not successful. Therefore, application of novel biological approaches such as immunotherapy, which appears to be more effective and less toxic, is necessary. Monoclonal antibodies against cancer specific antigens are a kind of immunotherapy that have been approved for specific types of cancer and are being investigated for prostate cancer as well. The aim of this review was to assess the effectiveness and safety of monoclonal antibodies for treatment of advanced prostate cancer. Method According to the search strategy stated in our systematic review protocol, Scopus, Medline, TRIP, CENTRAL, ProQuest, DART and OpenGrey databases were searched. Data collection and quality assessment were done independently by two authors and any disagreements between the collected data were resolved by a third author. A meta-analysis was not feasible as there was a considerable statistical heterogeneity among the trials. Hence, this review was limited to a narrative analysis of the included studies. Results We found 9756 references by applying search strategy in 4 databases of journal articles and 3 databases of grey literature. We then discarded 3957 duplicate citations using Endnote software and 5143 articles due to obvious irrelevancy of their topics in primary screening. In secondary screening of 656 fulltexts, we excluded 538 articles, and finally included 12 trials in this systematic review, updated on 23 June 2017. The overall quality of the studies was fair. In general, results of this systematic review show promising advances in the treatment of prostate cancer patients with monoclonal antibodies against prostate-specific antigens with regard to PSA/disease response. Some of the studies reported pain relief after treatment as well. Conclusion Currently, the role of immunotherapy in the treatment of advanced prostate cancer still remains debated. Although passive specific immunotherapy could be offered as a novel therapeutic option in the coming years, patients should be informed about the risks and benefits of this therapy. One of the obstacles in this review was the lack of adequate assessment of survival-related endpoints reported in the included studies. Our study provides support for further research in this field.

Innovations in imaging modalities for recurrent and metastatic prostate cancer: a systematic review

2018 ◽  
Vol 70 (4) ◽  
Author(s):  
Simone Albisinni ◽  
Fouad Aoun ◽  
Quentin Marcelis ◽  
Claude Jungels ◽  
Walid Al-Hajj Obeid ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Systematic Review ◽  
Metastatic Prostate Cancer ◽  
Imaging Modalities

Prognostic Impact of C-Reactive Protein in Metastatic Prostate Cancer: A Systematic Review and Meta-Analysis

2014 ◽  
Vol 37 (12) ◽  
pp. 772-776 ◽  
Author(s):  
Pedro Rocha ◽  
Charity J. Morgan ◽  
Arnoud J. Templeton ◽  
Gregory R. Pond ◽  
Gurudatta Naik ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Systematic Review ◽  
Metastatic Prostate Cancer ◽  
Meta Analysis ◽  
Prognostic Impact ◽  
C Reactive Protein ◽  
Reactive Protein

scholarly journals PARP Inhibitors in Metastatic Prostate Cancer: Evidence to Date

2020 ◽  
Vol Volume 12 ◽  
pp. 8105-8114 ◽  
Author(s):  
Emily Nizialek ◽  
Emmanuel S Antonarakis
Keyword(s):  
Prostate Cancer ◽  
Metastatic Prostate Cancer ◽  
Parp Inhibitors

Abstract 1091: Nuclear export inhibitor KPT-8602 synergize with PARP inhibitors in castration resistant metastatic prostate cancer

2021 ◽  
Author(s):  
Md. Hafiz Uddin ◽  
Yiwei Li ◽  
Amro Aboukameel ◽  
Husain Y. Khan ◽  
Vijendra Singh ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Nuclear Export ◽  
Metastatic Prostate Cancer ◽  
Parp Inhibitors ◽  
Castration Resistant
Sign in / Sign up

Export Citation Format

Share Document